Panjon Share Price
Sector: Biotechnology & Drugs
18.91 -0.23 (-1.20%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
18.85
Today’s High
19.42
52 Week Low
17.61
52 Week High
40.18
Key Metrics
- Market Cap (In Cr) 32.1
- Beta 0.83
- Div. Yield (%) 0
- P/B 1.96
- TTM P/E 77.25
- Sector P/E 22.43
- D/E 0
- Open Price 19.14
- Prev Close 19.14
Panjon Analysis
Price Analysis
-
1 Week-2.68%
-
3 Months-15.92%
-
6 Month-45.14%
-
YTD-39.24%
-
1 Year-1.87%
Risk Meter
- 44% Low risk
- 44% Moderate risk
- 44% Balanced Risk
- 44% High risk
- 44% Extreme risk
Panjon Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 30.46
- Selling/ General/ Admin Expenses Total
- 1.37
- Depreciation/ Amortization
- 0.23
- Other Operating Expenses Total
- 2.48
- Total Operating Expense
- 30.07
- Operating Income
- 0.39
- Net Income Before Taxes
- 0.53
- Net Income
- 0.53
- Diluted Normalized EPS
- 0.31
- Period
- 2025
- Total Assets
- 20.05
- Total Liabilities
- 3.51
- Total Equity
- 16.54
- Tangible Book Valueper Share Common Eq
- 9.63
- Period
- 2025
- Cashfrom Operating Activities
- -4.34
- Cashfrom Investing Activities
- -0.44
- Cashfrom Financing Activities
- 2.5
- Net Changein Cash
- -2.27
- Period
- 2024
- Total Revenue
- 12.55
- Selling/ General/ Admin Expenses Total
- 0.6
- Depreciation/ Amortization
- 0.22
- Other Operating Expenses Total
- 3.03
- Total Operating Expense
- 12.81
- Operating Income
- -0.26
- Net Income Before Taxes
- 0.16
- Net Income
- 0.15
- Diluted Normalized EPS
- 0.1
- Period
- 2024
- Total Assets
- 17.39
- Total Liabilities
- 2.54
- Total Equity
- 14.85
- Tangible Book Valueper Share Common Eq
- 9.1
- Period
- 2024
- Cashfrom Operating Activities
- -0.42
- Cashfrom Investing Activities
- -0.21
- Cashfrom Financing Activities
- 1.88
- Net Changein Cash
- 1.25
- Period
- 2023
- Total Revenue
- 6.09
- Selling/ General/ Admin Expenses Total
- 0.47
- Depreciation/ Amortization
- 0.21
- Other Operating Expenses Total
- 3.55
- Total Operating Expense
- 6.31
- Operating Income
- -0.22
- Net Income Before Taxes
- 0.12
- Net Income
- 0.81
- Diluted Normalized EPS
- 0.52
- Period
- 2023
- Total Assets
- 14.9
- Total Liabilities
- 1.42
- Total Equity
- 13.48
- Tangible Book Valueper Share Common Eq
- 8.69
- Period
- 2023
- Cashfrom Operating Activities
- 0.04
- Cashfrom Investing Activities
- -0.19
- Cashfrom Financing Activities
- 0.18
- Net Changein Cash
- 0.04
- Period
- 2022
- Total Revenue
- 8.43
- Selling/ General/ Admin Expenses Total
- 0.46
- Depreciation/ Amortization
- 0.2
- Other Operating Expenses Total
- 7.52
- Total Operating Expense
- 12.68
- Operating Income
- -4.25
- Net Income Before Taxes
- -4.01
- Net Income
- -4.15
- Diluted Normalized EPS
- -2.68
- Period
- 2022
- Total Assets
- 14.05
- Total Liabilities
- 1.38
- Total Equity
- 12.66
- Tangible Book Valueper Share Common Eq
- 8.16
- Period
- 2022
- Cashfrom Operating Activities
- 1.82
- Cashfrom Investing Activities
- -0.19
- Cashfrom Financing Activities
- -0.51
- Net Changein Cash
- 1.12
- Period
- 2021
- Total Revenue
- 14.54
- Selling/ General/ Admin Expenses Total
- 0.42
- Depreciation/ Amortization
- 0.23
- Other Operating Expenses Total
- 2.17
- Total Operating Expense
- 14.58
- Operating Income
- -0.04
- Net Income Before Taxes
- 0.19
- Net Income
- 0.1
- Diluted Normalized EPS
- 0.06
- Period
- 2021
- Total Assets
- 19.25
- Total Liabilities
- 2.44
- Total Equity
- 16.81
- Tangible Book Valueper Share Common Eq
- 10.84
- Period
- 2021
- Cashfrom Operating Activities
- 0.34
- Cashfrom Investing Activities
- -0.06
- Cashfrom Financing Activities
- -0.24
- Net Changein Cash
- 0.04
- Period
- 2020
- Total Revenue
- 26.43
- Selling/ General/ Admin Expenses Total
- 0.47
- Depreciation/ Amortization
- 0.27
- Other Operating Expenses Total
- 2.11
- Total Operating Expense
- 26.38
- Operating Income
- 0.05
- Net Income Before Taxes
- 0.19
- Net Income
- -0.03
- Diluted Normalized EPS
- -0.02
- Period
- 2020
- Total Assets
- 19.21
- Total Liabilities
- 2.49
- Total Equity
- 16.73
- Tangible Book Valueper Share Common Eq
- 10.79
- Period
- 2020
- Cashfrom Operating Activities
- 0.35
- Cashfrom Investing Activities
- -0.51
- Cashfrom Financing Activities
- -0.07
- Net Changein Cash
- -0.22
- Period
- 2019
- Total Revenue
- 25.94
- Selling/ General/ Admin Expenses Total
- 0.34
- Depreciation/ Amortization
- 0.15
- Other Operating Expenses Total
- 2.41
- Total Operating Expense
- 25.82
- Operating Income
- 0.12
- Net Income Before Taxes
- 0.28
- Net Income
- 0.14
- Diluted Normalized EPS
- 0.09
- Period
- 2019
- Total Assets
- 18.95
- Total Liabilities
- 2.18
- Total Equity
- 16.77
- Tangible Book Valueper Share Common Eq
- 10.82
- Period
- 2019
- Cashfrom Operating Activities
- 0.49
- Cashfrom Investing Activities
- -0.31
- Cashfrom Financing Activities
- -0.05
- Net Changein Cash
- 0.13
- Period
- 2025-03-31
- Total Revenue
- 13.83
- Selling/ General/ Admin Expenses Total
- 0.15
- Depreciation/ Amortization
- 0.08
- Other Operating Expenses Total
- 0.94
- Total Operating Expense
- 13.59
- Operating Income
- 0.24
- Net Income Before Taxes
- 0.23
- Net Income
- 0.23
- Diluted Normalized EPS
- 0.13
- Period
- 2025-03-31
- Total Assets
- 20.05
- Total Liabilities
- 3.51
- Total Equity
- 16.54
- Tangible Book Valueper Share Common Eq
- 9.63
- Period
- 2025-03-31
- Cashfrom Operating Activities
- -4.34
- Cashfrom Investing Activities
- -0.44
- Cashfrom Financing Activities
- 2.5
- Net Changein Cash
- -2.27
- Period
- 2024-12-31
- Total Revenue
- 11.16
- Selling/ General/ Admin Expenses Total
- 0.4
- Depreciation/ Amortization
- 0.05
- Other Operating Expenses Total
- 0.86
- Total Operating Expense
- 10.98
- Operating Income
- 0.17
- Net Income Before Taxes
- 0.2
- Net Income
- 0.2
- Diluted Normalized EPS
- 0.12
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 3.38
- Selling/ General/ Admin Expenses Total
- 0.41
- Depreciation/ Amortization
- 0.05
- Other Operating Expenses Total
- 0.35
- Total Operating Expense
- 3.37
- Operating Income
- 0.01
- Net Income Before Taxes
- 0.07
- Net Income
- 0.07
- Diluted Normalized EPS
- 0.04
- Period
- 2024-09-30
- Total Assets
- 17.95
- Total Liabilities
- 3.43
- Total Equity
- 14.52
- Tangible Book Valueper Share Common Eq
- 8.9
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -1.37
- Cashfrom Investing Activities
- 0
- Cashfrom Financing Activities
- 0.63
- Net Changein Cash
- -0.74
- Period
- 2024-06-30
- Total Revenue
- 2.09
- Selling/ General/ Admin Expenses Total
- 0.41
- Depreciation/ Amortization
- 0.05
- Other Operating Expenses Total
- 0.33
- Total Operating Expense
- 2.13
- Operating Income
- -0.04
- Net Income Before Taxes
- 0.03
- Net Income
- 0.03
- Diluted Normalized EPS
- 0
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 5.2
- Selling/ General/ Admin Expenses Total
- -0.57
- Depreciation/ Amortization
- 0.16
- Other Operating Expenses Total
- 1.52
- Total Operating Expense
- 5.41
- Operating Income
- -0.2
- Net Income Before Taxes
- 0.05
- Net Income
- 0.05
- Diluted Normalized EPS
- 0.03
- Period
- 2024-03-31
- Total Assets
- 17.39
- Total Liabilities
- 2.54
- Total Equity
- 14.85
- Tangible Book Valueper Share Common Eq
- 9.1
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -0.42
- Cashfrom Investing Activities
- -0.21
- Cashfrom Financing Activities
- 1.88
- Net Changein Cash
- 1.25
- Period
- 2023-12-31
- Total Revenue
- 4.81
- Selling/ General/ Admin Expenses Total
- 0.37
- Depreciation/ Amortization
- 0.02
- Other Operating Expenses Total
- 0.72
- Total Operating Expense
- 4.82
- Operating Income
- -0.01
- Net Income Before Taxes
- 0.04
- Net Income
- 0.04
- Diluted Normalized EPS
- 0.03
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Panjon Technical
Moving Average
SMA
- 5 Day19.29
- 10 Day19.67
- 20 Day19.92
- 50 Day20.23
- 100 Day20.75
- 300 Day22.15
Panjon Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Ang Lifesciences India
- 28
- 0.17
- 0.61
- 62.75
- 21.03
- 36.56
- Transgene Biotek
- 4.42
- -0.09
- -2
- 10.84
- 3.22
- 29.07
- Panjon
- 18.91
- -0.23
- -1.2
- 40.18
- 17.61
- 32.1
- Aryavan Enterprise
- 45
- -0.02
- -0.04
- 69.74
- 31.57
- 25.92
- Concord Drugs
- 36
- 4.79
- 15.35
- 44.96
- 26.1
- 35.33
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Ang Lifesciences India
- -
- 0.57
- 7.28
- 2.53
- Transgene Biotek
- -
- -
- -49.74
- -3491.86
- Panjon
- 62.3
- 1.99
- -3.45
- -3.56
- Aryavan Enterprise
- 14.38
- 1.05
- 4.77
- 3.29
- Concord Drugs
- 91.79
- 0.91
- 4.46
- 2.64
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-May-25
- Audited Results
- 14-Feb-25
- Quarterly Results
- 24-Dec-24
- Preferential Issue of shares & Others
- 14-Nov-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results
- 28-Jun-24
- Preferential issue of shares
- 27-May-24
- Audited Results
- 13-Feb-24
- Quarterly Results
- 02-Feb-24
- Preferential issue of shares
- 08-Nov-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 30-Sept-23
- 01-Sept-23
- AGM
- -
- 19-Aug-24
- AGM



